{"groups":[{"description":"Arm A: Patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation were treated with bortezomib, lenalidomide, and dexamethasone for induction and consolidation followed by lenalidomide maintenance in 28-day cycles. After 4 cycles of induction, patients received high dose therapy with autologous stem cell transplantation.","id":"FG000","title":"Velcade Lenalidomide Dexamethasone (VRd)"},{"description":"Arm B: Patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation were treated with subcutaneous daratumumab in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation followed by subcutaneous daratumumab in combination with lenalidomide maintenance in 28-day cycles. After 4 cycles of induction, patients received high dose therapy with autologous stem cell transplantation.","id":"FG001","title":"Daratumumab + VRd (D-VRd)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"44"},{"groupId":"FG001","numSubjects":"34"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"5"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"10"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"354"},{"groupId":"FG001","numSubjects":"355"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"295"},{"groupId":"FG001","numSubjects":"306"}],"comment":"Participants that are still on study are listed as \"completed\"","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"59"},{"groupId":"FG001","numSubjects":"49"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}